Amneal Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amneal Pharmaceuticals (AMRX) Misses Q3 EPS by 10c, Lowers FY EPS Guidance
November 6, 2019 6:43 AM ESTAmneal Pharmaceuticals (: AMRX) reported Q3 EPS of $0.04, $0.10 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $378.3 million versus the consensus estimate of $408.98 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2019 EPS of $0.31, versus the consensus of... More
